NEW YORK (GenomeWeb News) – An international consortium of researchers has developed a mass spectrometry-based reference method for standardizing measurements of cerebrospinal fluid amyloid beta 42 levels in Alzheimer's disease research and clinical work.

The method will allow researchers and clinicians to compare CSF Aβ42 measurements made with different assays in different labs, something that is currently not possible due to differences between these assays, said Henrik Zetterberg, a researcher at Sweden's Gothenburg Universityand one of the leaders of the effort.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.

Jul
12
Sponsored by
Canon BioMedical

This webinar will discuss a project that is analyzing the “Human Brainome” – genome, transcriptome, proteome, and phenome interaction data -- to gain insights into Alzheimer’s disease pathogenesis.